Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.39 |
| ▸ | GRN | P28799 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199674 | 0.84 | PRKCZ (0.48) | PRKCZALDH1A1L3MBTL1CDK8MAPK14 | |
| SCHEMBL17885745 | 0.82 | POLB (0.44) | PRKCZALDH1A1L3MBTL1CDK8MAPK14 | |
| SCHEMBL4502798 | 0.81 | CDK8 (0.58) | CDK8MAPK14MAPK9DDR2GAA | |
| SCHEMBL14314274 | 0.80 | PRKCZ (0.55) | PRKCZCDK8MAPK14GRNSORT1 | |
| SCHEMBL9910542 | 0.77 | CDK8 (0.55) | CDK8MAPK14GRNSORT1DDR2 | |
| SCHEMBL16910835 | 0.75 | PRKCZ (0.45) | PRKCZALDH1A1L3MBTL1MAPK14 | |
| SCHEMBL1695803 | 0.75 | PRKCZ (0.41) | PRKCZALDH1A1GAASIGMAR1 | |
| SCHEMBL12847029 | 0.73 | CDK8 (0.44) | L3MBTL1CDK8MAPK14GRNSORT1 | |
| SCHEMBL13056309 | 0.73 | GRN (0.61) | ALDH1A1MAPK14GRNSORT1GAA | |
| SCHEMBL4205964 | 0.72 | PRKCZ (0.57) | PRKCZALDH1A1L3MBTL1CDK8MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
| WO-2010094956-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED. (GB) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CNKSR1, MOK, MAPK1 | PRKCZ 316/4885ALDH1A1 1860/4885L3MBTL1 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.